We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Biotech for less than cash value
An SI Board Since April 2002
Posts SubjectMarks Bans
538 120 0
Emcee:  RWReeves Type:  Unmoderated
At market bottoms in the land of Biotech stocks, a rather odd phenomena occurs. Some, indeed many, stocks which move so much on "story" and so little on actual financial analysis, sell for very, very little money. Now just cheap is not enough for us. Nay, we want value. Extreme value. We want candidates selling for less than cash in the bank, for less than liquidation value preferably

Old timers who remember the previous market bottoms will often share with wonder stories- (indeed fantasies of buying control of a stock for less than cash and selling off the assets) situations where there was some reasonable value of the technology, no impossibly large liability, and yet more cash per share than the market price. Sometimes these companies prove irresistable to other BTs or pharmas in mergers and takeovers. Sometimes the market "comes to it's senses". Other times they had a fatal flaw and could not recover from the spiral and the cash was burned to no avail.

Now this is another no-man's land where one should not wander carelessly. These represent very speculative investments by their nature and you MUST take responsibility for your own investment decisions and do your own analysis.

With that, I invite discussion and nominations of candidate biotechs selling currently for less than cash or liquidation value and will be putting some into a model portfolio.

Please don't use the forum for pumping a stock- and provide as much of a reasoned analysis or link to hard data as possible. This forum is un-moderated, you have only your credibility at risk by pumping one way or the other. Disclosure of interest is strongly encouraged.

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
538ARDX soars today. It was high on my watch list, but I never Bladerunner17-September 3
537Updated for Q2 burn. 59 at or below cash, by my calcs 16 of which will be aboverkrw1August 26
536What do you think, stock has at least doubled since? Synageva the standard bearkrw-August 7
535We should create an a priori definition of "worked out" so as not to bDewDiligence_on_SI-August 6
534Good stuff. I'll have to poke around on that, would be curious what % of revrkrw-August 6
533Totally agree. But do think there are a few CEOs of cash-rich biotechs who’ve shBulbaMan-August 5
532That’s business development and completely different. BD is hard, not so many arrkrw1August 5
531The Biotech Buyouts table referenced in the header of the iHub BV board includesDewDiligence_on_SI1August 5
530Thanks RKRW, but not the kind of deal that I’m looking for. ;~) Amount of RLM caBulbaMan-August 5
529I stand corrected, came across this one that traded their cash for equivalent shrkrw-August 5
528CABG liquidation: investorshub.advfn.comDewDiligence_on_SI-July 30
527CABG but it's a while ago. And heart valve replacement rather than drug.Lance Bredvold-July 30
526>>>I guess IMDZ had something worth buying... As you may remember, my BulbaMan-July 29
525I guess IMDZ had something worth buying and a willing buyer. Then there are corkrw-July 27
524@buysidebio posted this on Twitter recently: "Biotech & Pharma names wbmaz001-July 27
523For sure, the CEO’s reputation for deal-making and self-dealing would be a factoBulbaMan-July 27
522I can't remember the last biotech that did a simple dissolve and return the rkrw1July 27
521That’s not surprising. But I’m guessing there are more than a handful that have BulbaMan-July 27
520Many of the names are less cash rich, than market cap poor. rkrw1July 27
519Thanks for posting the list! I wonder if it would be useful to check for the ageBulbaMan-July 27
518First hit, Jounce with a $50m upfront from Celgene,.rkrw1July 24
51762 names below cash. Bear in mind, numbers aren't updated for Q2 ending cashrkrw1July 23
516All disclosed before but here's what they get as a reward for running the corkrw-June 3
515VICL actually got much more equity in the merged company (40%) than you typicallDewDiligence_on_SI-June 3
514Wow. wtf. A very deserved -20%. brickellbio.comkeokalani'nui-June 3
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):